Estimating future hepatitis C morbidity, mortality, and costs in the United States

American Journal of Public Health

Volumn 90, Issue 10, 2000, Pages 1562-1569

  Wong, J B ^a   McQuillan, G M ^a   McHutchison, J G ^a   Poynard, T ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL CONSUMPTION; ARTICLE; CHRONIC LIVER DISEASE; COMPUTER SIMULATION; ECONOMIC ASPECT; HEALTH CARE COST; HEPATITIS C; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MORBIDITY; MORTALITY; UNITED STATES;

EID: 0033799722     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.90.10.1562     Document Type: Article

References (60)

1. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
2. The epidemiology of viral hepatitis in the United States
3. Management of hepatitis C
4. Chronic liver disease deaths associated with viral hepatitis in the United States
5. A population based serologic study of hepatitis C in the United States
6. The prevalence of hepatitis C virus infection in the United States: 1988 Through 1994
7. Hepatitis C: The clinical spectrum of disease
8. Chronic liver disease mortality in the United States, 1979 through 1989
9. Births and deaths: Preliminary data for 1997
10. Interferon treatment for chronic hepatitis B or C infection: Costs and effectiveness
11. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C
12. The Markov Process in medical prognosis
13. Markov models in medical decision making: A practical guide
14. Pre-treatment evaluation of chronic hepatitis C: Risks, benefits and costs
15. Classification of chronic hepatitis: Diagnosis, grading, and staging
16. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94
17. Natural history of liver fibrosis progression in patients with chronic hepatitis C: The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups
18. Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up
19. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis
20. Natural course of chronic hepatitis C
21. Morbidity and mortality in compensated cirrhosis type C. A retrospective follow-up study of 384 patients
22. Survival and prognostic factors of cirrhotic patients with ascites: A study of 134 outpatients
23. Sclerotherapy for male alcoholic cirrhotic patients who have bled from esophageal vafices: Results of a randomized, multicenter clinical trial
24. Prognosis after the first episode of gastrointestinal bleeding or coma in cirrhosis: Survival and prognostic factors
25. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: Study of 850 patients
26. An analysis of liver transplant experience from 37 transplant centers as reported to Medicare
27. Liver transplantation for hepatitis C virus-related cirrhosis
28. Liver transplantation for chronic viral hepatitis
29. European Association for the Study of the Liver
30. Non-A, non-B post-transfusion hepatitis: Looking back in the second decade
31. Addict death rates during a four-year posttreatment follow-up
32. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
33. Life expectancy biases in clinical decision modeling
34. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis: A prospective study
35. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis
36. Characteristics of patients with dual infection by hepatitis B and C viruses
37. Cancer statistics, 1991
38. Hepatobiliary neoplasms
39. Presence of antibodies to the hepatitis B surface antigen is associated with an excess risk for hepatocellular carcinoma among non-Asians in Los Angeles County, California
40. Hepatitis C and hepatocellular carcinoma
41. Rising incidence of hepatocellular carcinoma
42. Impact of alcohol on the histological and clinical progression of hepatitis C infection
43. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group
44. Occupational exposure to hepatitis C virus: A dilemma
45. Hepatitis C and the correctional population
46. Projecting the future healthcare burden from hepatitis C in the United States [abstract]
47. Modeling the hepatitis C virus epidemic in France
48. The distinction between cost and charges
49. The cost of dying of end-stage liver disease
50. Hepatitis C: A sleeping giant?